Axonara Biosciences develops technology to establish a rapid diagnostic layer for genomic medicine applications. The company focuses on accelerating the turnaround time for complex genetic analysis. This platform enables faster, more efficient clinical decision-making based on genomic data.
Funding
Funding not disclosed
Founders
Product
Problem
Cerebral cavernous malformations (CCMs) are often underdiagnosed due to the limitations of traditional diagnostic methods, particularly in resource-limited settings. Current diagnostic processes can be slow, costly, and require specialized equipment and expertise, hindering early detection and timely intervention.
Solution
Axonara provides an integrated diagnostic platform for cerebral cavernous malformations (CCMs), combining genetic screening with AI-powered imaging analysis to improve early detection and monitoring. The platform features a portable PCR device for rapid genetic testing, enabling point-of-care diagnostics. AI-driven imaging analysis offers real-time assessment and remote monitoring capabilities. By integrating these technologies, Axonara aims to enhance diagnostic accuracy and accessibility, particularly in underserved communities.
Target Audience
The primary target audience includes neurologists, healthcare providers in resource-limited settings, and clinical researchers focused on cerebral cavernous malformations.
Features
- Portable PCR device for rapid genetic screening at the point-of-care
- AI-powered imaging analysis for accurate CCM detection and monitoring
- Real-time image analysis capabilities
- Cloud integration for data storage and accessibility
- Remote monitoring functionalities